InsidersTradesSigma
Total declarations
Companies
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
13
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Ginocchio Paul, Chief Financial Officer. Insider active across 2 companies, notably Augmedix, Inc.. In total, 16 disclosures have been published. Split: 13 buys · 0 sell. Total volume traded: €635k. Activity tracked since 19 May 2021. The latest transaction was filed on 2 October 2024 (Disposition). Regulator: SEC (Form 4). All data is free.
Declarations16 total
135,795 shares@ US$2.3573.2% of flowCommon StockSEC:0001213900-24-085356:0
6,250 sharesCommon StockSEC:0001213900-24-070865:0
6,250 sharesCommon StockSEC:0001213900-24-044880:0
10,000 shares@ US$4.8511.3% of flowCommon StockSEC:0001213900-23-089962:0
Ideal exit: 18 Aug 2024 (T+270)
18,000 shares@ US$1.205.2% of flowCommon StockSEC:0001213900-22-080096:0
Ideal exit: 9 Sept 2023 (T+270)
16,000 shares@ US$1.995.6% of flowCommon StockSEC:0001213900-22-030198:0
Ideal exit: 20 Feb 2023 (T+270)
14,000 shares@ US$2.967.0% of flowCommon StockSEC:0001213900-21-061681:0
Ideal exit: 20 Aug 2022 (T+270)
14,000 shares@ US$2.967.0% of flowCommon StockSEC:0001213900-21-061681
Ideal exit: 20 Aug 2022 (T+270)
34,000 shares@ US$4.0022.0% of flowCommon StockSEC:0001213900-21-055923:0
Ideal exit: 25 Jul 2022 (T+270)
34,000 shares@ US$4.0022.0% of flowCommon StockSEC:0001213900-21-055923
Ideal exit: 25 Jul 2022 (T+270)
10,000 shares@ US$5.007.8% of flowCommon StockSEC:0001213900-21-031673:0
Ideal exit: 4 Mar 2022 (T+270)
10,000 shares@ US$5.007.8% of flowCommon StockSEC:0001213900-21-031673
Ideal exit: 4 Mar 2022 (T+270)
9,356 shares@ US$4.566.6% of flowCommon StockSEC:0000899243-21-020924
Ideal exit: 19 Feb 2022 (T+270)
9,356 shares@ US$4.566.6% of flowCommon StockSEC:0000899243-21-020924:0
Ideal exit: 19 Feb 2022 (T+270)
12,600 shares@ US$3.96100.0% of flowCommon StockSEC:0000899243-21-020403
Ideal exit: 13 Feb 2022 (T+270)
12,600 shares@ US$3.967.8% of flowCommon StockSEC:0000899243-21-020403:0
Ideal exit: 13 Feb 2022 (T+270)
16 of 16 declarations
About Ginocchio Paul
Paul Ginocchio is the Chief Financial Officer at Augmedix, Inc. He is responsible for the company's financial management, overseeing accounting and financial operations. His role is crucial in ensuring the financial health of the company and supporting strategic decision-making. He brings his expertise in finance and management to guide the company's activities.
